NASDAQ
1.01USD
-0.01 (-1.46%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
122.7M
P/E
—
EPS
—
Beta
0.78
52W range
0.161-3.39
Day range
1.00–1.06
Open
1.00
Prev close
1.03
Volume
1M
Avg volume
19.8M
Dividend
0.00
IPO
2016-06-14
https://www.globenewswire.com/news-release/2026/08/06/3340307/0/en/Outlook-Therapeutics-to-Report-Third-Quarter-Fiscal-Year-2026-Financial-Results-and-Host-a-Corporate-Update-Conference-Call-and-Webcast-on-August-14-2026.html · 8/6/2026+0.00
https://seekingalpha.com/article/4926451-outlook-hold-caution-on-lytenava-fda-approval-and-cash-needs · 7/28/2026-0.20
https://seekingalpha.com/article/4912616-outlook-therapeutics-potential-catalysts-offering-an-arbitrage-opportunity · 6/6/2026+0.60
https://www.globenewswire.com/news-release/2026/06/01/3304397/0/en/Outlook-Therapeutics-Announces-Resubmission-of-Biologics-License-Application-to-U-S-FDA-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html · 6/1/2026+0.80
https://www.zacks.com/stock/news/2922221/oncobiologics-inc-otlk-reports-q2-loss-lags-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2922221 · 5/15/2026-0.80
https://www.globenewswire.com/news-release/2026/05/15/3296119/0/en/Outlook-Therapeutics-Reports-Second-Quarter-Fiscal-Year-2026-Financial-Results-and-Provides-Corporate-Update.html · 5/15/2026+0.40
https://www.globenewswire.com/news-release/2026/04/07/3269178/0/en/Outlook-Therapeutics-Announces-Formal-Dispute-Resolution-Request-for-ONS-5010-LYTENAVA-bevacizumab-vikg-Accepted-by-FDA.html · 4/7/2026+0.80
https://www.globenewswire.com/news-release/2026/03/23/3260887/0/en/Outlook-Therapeutics-Announces-Proposed-Public-Offering.html · 3/23/2026-0.20
https://www.benzinga.com/markets/market-summary/26/01/49687357/dow-jumps-over-300-points-on-first-trading-day-of-2026-fear-greed-index-remains-in-neutral-zone · 1/5/2026-1.00
https://seekingalpha.com/article/4856076-third-time-the-charm-outlook-therapeutics-lytenava-heads-to-fda-again · 12/29/2025+0.40
https://www.globenewswire.com/news-release/2025/09/29/3157742/0/en/Outlook-Therapeutics-Provides-Update-on-Type-A-Meeting-with-FDA.html · 9/29/2025+0.30
https://www.zacks.com/stock/news/2744881/otlk-stock-crashes-54-as-fda-issues-second-crl-for-eye-disease-drug?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2744881 · 8/29/2025-1.00
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
